Alcon Inc. (ALC)
ALC vs. PEN: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Alcon Inc (ALC) Stock Down 3.1% -- Now Undervalued? GF Score: 80/100
On April 21, 2026, Alcon Inc (ALC) shares fell 3.1% today to a current price of $77.82. This decline comes amid a 52-week range of $71.55 to $99.20, reflecting
Are Medical Stocks Lagging Alcon (ALC) This Year?
Here is how Alcon (ALC) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid
STAAR Surgical Company has seen a dramatic valuation reset, now trading at a $1bn market cap after failed acquisition talks and underwhelming US growth. Q1 2026 net sales are expected to exceed $90m, driven by a strong rebound in China and signaling potential for record annual revenues. Despite operational challenges and competitive pressures, STAA's proprietary Collamer lens and expanded US indications provide incremental growth opportunities.
Alcon Stock Gains Following the Launch of Clareon TruPlus at ASCRS
ALC gains after launching Clareon TruPlus IOL, expanding its portfolio with enhanced depth of focus while maintaining high-quality distance vision.
5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
Here is how Alcon (ALC) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
Why Alcon (ALC) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alcon's Q4 Earnings Miss Estimates, Stock Falls, Revenues Rise Y/Y
ALC's Q4 EPS and revenues lag estimates, sending shares down 3%, even as sales increase 9% and 2026 guidance targets up to 7% growth.
Eye-care group Alcon expects product launches to drive 2026 sales, profitability
Alcon on Tuesday forecast 2026 sales growth largely in line with market estimates and guided for a significant expansion in its operating margin, signalling confidence that product launches would drive improved profitability.
Alcon (ALC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alcon Inc. (ALC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alcon Inc. (ALC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
